NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability

Journal of Medicinal Chemistry

Volumn 45, Issue 26, 2002, Pages 5628-5639

  Hajduk, Philip J ^a   Shuker, Suzanne B ^a,b   Nettesheim, David G ^a   Craig, Richard ^a   Augeri, David J ^a,c   Betebenner, David ^a   Albert, Daniel H ^a   Guo, Yan ^a   Meadows, Robert P ^a   Xu, Lianhong ^a   Michaelides, Michael ^a   Davidsen, Steven K ^a   Fesik, Stephen W ^a  

^a ABBOTT LABORATORIES   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHYLHYDROXAMATE; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CATALYTIC DOMAIN; HYDROXAMIC ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; NAPHTHALENES; PROTEASE INHIBITORS; PROTEIN BINDING; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037137618     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020160g     Document Type: Article

References (19)

1. Docherty, A. J. P.; O'Connell, J.; Crabbe, T.; Angal, S.; Murphy, G. The matrix metalloproteinases and their natural inhibitors: Prospects for treating degenerative tissue diseases. Trends Biotechnol. 1992, 10, 200-207.
2. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today 1996, 1, 16-26.
3. Beckett, R. P.; Whittaker, M. Matrix metalloproteinase inhibitors 1998. Exp. Opin. Ther. Patents 1998, 8, 259-282.
4. Steward, W. P. Marimistat (BB2516): Current status of development. Cancer Chemother. Pharmacol. 1999, 43, S56-60.
5. Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P. et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N. Y. Acad. Sci. 1999, 878, 236-270.
6. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R. L. et al. Discovery of CGS 27023A, a nonpeptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532.
7. Singh, J.; Conzentino, P.; Cundy, P.; Gainor, J. A.; Gilliam, C. L. et al. Relationship between structure and bioavailability in a series of hydroxamate based metalloprotease inhibitors. Bioorg. Med. Chem. Lett. 1995, 5, 337-342.
8. Summers, J. B.; Gunn, B. P.; Mazdiyasni, H.; Goetze, A. M.; Young, P. R. et al. J. Med. Chem. 1987, 30, 2121-2126.
9. Peng, S. X.; Strojnowski, M. J.; Hu, J. K.; Smith, B. J.; Eichhold, T. E. et al. Gas chromatographic-mass spectrometric analysis of hydroxylamine for monitoring hydrolysis of metalloprotease inhibitors in rat and human liver microsomes. J. Chromatogr. B 1999, 724, 181-187.
10. Hajduk, P. J.; Gomtsyan, A.; Didomenico, S.; Cowart, M.; Bayburt, E. K. et al. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J. Med. Chem. 2000, 43, 4781-4786.
11. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B. et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 1997, 119, 5818-5827.
12. Michaelides, M.; Dellaria, J.; Gong, J.; Holms, J.; Bouska, J. et al. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. Biorg. Med. Chem. Lett. 2001, 11, 1553-1556.
13. Wada, C. K.; Holms, J. H.; Curtin, M. L.; Dai, Y.; Florjancic, A. S. et al. Phenoxyphenyl sulfone N-Formylhydroxylamines (Retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J. Med. Chem. 2002, 45, 219-232.
14. Migdalof, B. H.; Antonaccio, M. J.; McKinstry, D. N.; Singhvi, S. M.; Lan, S.-J. et al. Captopril: Pharmacology, metabolism, and disposition. Drug. Metab. Rev. 1984, 15, 841-869.
15. It should be noted that the inhibitory activity observed in the blood during the PK studies cannot formally be attributed to the parent compound, as an active metabolite could also contribute to enzymatic inhibition. However, the most likely metabolite would be the corresponding carboxylic acid, which would be predicted to have little or no activity (See ref 2). In fact, the carboxylic analogue of the initial inhibitor 3 exhibited a more than 100-fold loss in potency compared to the hydroxamate-containing parent (ref 12).
16. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531-1534.
17. Hajduk, P. J.; Boyd, S.; Nettesheim, D.; Nienaber, V.; Severin, J. et al. The identification of novel inhibitors of urokinase using NMR-based screening. J. Med. Chem. 2000, 43, 3862-3866.
18. Meadows, R. P.; Hajduk, P. J. A genetic algorithm-based protocol for docking ensembles of small ligands using experimental restraints. J. Biomol. NMR 1995, 5, 41-47.
19. Brunger, A. T. X-PLOR Version 3.1.; Yale University Press: New Haven and London, 1992.